Form 4: BioXcel CSO Converts RSUs to Common Stock

BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, converted Restricted Stock Units into common stock on December 14 and 15, 2025.

Summary

• Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, Inc. (BTAI), converted Restricted Stock Units (RSUs) into common stock.
• On December 14, 2025, 33 RSUs were converted into 33 shares of common stock.
• On December 15, 2025, 35 RSUs were converted into 35 shares of common stock.
• Following these transactions, Yocca directly beneficially owns 6,452 shares of common stock and 282 Restricted Stock Units.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction where the Chief Scientific Officer converted Restricted Stock Units into common stock. This is a standard compensation event and generally viewed as neutral to slightly positive as it increases direct insider ownership, aligning executive interests with shareholders, without indicating any new strategic developments or financial performance.

Positives

• Chief Scientific Officer Frank Yocca increased his direct beneficial ownership of BioXcel Therapeutics common stock by 68 shares through RSU conversions.
• The conversion of RSUs into common stock indicates a vesting event, aligning management's interests with shareholders.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• NA

Industry Context

This Form 4 filing details a routine insider transaction, specifically the conversion of Restricted Stock Units (RSUs) into common stock by a key executive. Such transactions are common in the biotechnology and pharmaceutical industries as part of executive compensation packages, designed to align management incentives with long-term shareholder value.

Comparison to Industry Standards

• The RSU vesting schedule (25% on first anniversary, then 6.25% quarterly) is a common practice in executive compensation plans across the biotechnology sector, similar to those seen at companies like Moderna or Pfizer for their key scientific personnel.
• The conversion of RSUs at a $0 exercise price is standard for these types of equity awards, reflecting the grant of full-value shares upon vesting, which is a prevalent compensation structure in growth-oriented industries.

Stakeholder Impact

• Shareholders: Increased insider ownership may be seen as a positive signal of management's confidence in the company's long-term prospects.
• Employees: The vesting of RSUs is a standard component of executive compensation, reinforcing the company's commitment to performance-based incentives.

Next Steps

• Continued vesting of remaining Restricted Stock Units according to the established schedules from March 14, 2022, and March 15, 2023, subject to continuous employment.

Key Dates

Recommendation

This Form 4 details a routine conversion of Restricted Stock Units (RSUs) into common stock by a key executive. While it increases insider ownership, which is generally a positive signal, it does not provide new information regarding the company's financial performance, strategic direction, or operational results that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate, maintaining current positions based on existing company fundamentals and market outlook.

Keywords

BTAI, BioXcel Therapeutics, Frank Yocca, Form 4, Insider Transaction, RSU Conversion, Common Stock, Chief Scientific Officer